论文部分内容阅读
目的探讨清开灵和还原型谷胱甘肽对药物性肝炎的临床疗效。方法采用前瞻性研究,对2007年6月～2009年5月诊断为抗结核药物性肝炎228例患者随机分为治疗组114例和对照组114例,前者予清开灵和还原型谷胱甘肽治疗,后者进行常规护肝治疗,治疗2～4周对疗效进行统计学分析。结果结核药物性肝炎大多发生于强化期内,治疗组的疗效显著优于对照组,2组间1周内有效率差异有统计学意义(P<0.05)。结论清开灵和还原型谷胱甘肽治疗1周内可明显改善药物性肝炎表现及恢复肝功能作用,对于结核药物性肝炎有较好疗效,而且临床应用安全,值得推广应用。
Objective To investigate the clinical efficacy of Qingkailing and reduced glutathione on drug-induced hepatitis. Methods A prospective study of 228 patients diagnosed with anti-TB drug-induced hepatitis from June 2007 to May 2009 were randomly divided into treatment group (114 cases) and control group (114 cases). The former was treated with Qingkailing and reduced glutathione Peptide therapy, the latter for conventional liver protection treatment for 2 to 4 weeks for statistical analysis of efficacy. Results Most of the drug-induced hepatitis in tuberculosis occurred during the intensive phase. The curative effect of the treatment group was significantly better than that of the control group. There was a significant difference in the effective rate between the two groups within 1 week (P <0.05). Conclusion Qing Kai Ling and reduced glutathione treatment within 1 week can significantly improve the performance of drug-induced hepatitis and restore liver function, for tuberculosis drug-induced hepatitis has a good effect, and clinical safety, it is worth promoting the application.